Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 401 - 450 out of 7,137

Document Document Title
WO/2016/017466A1
Provided is a noxious arthropod control agent containing an amide compound represented by formula (I) [In the formula, X represents a nitrogen atom or CH group, p represents 0 or 1, A represents a tetrahydrofuranyl group or the like, R1,...  
WO/2016/009296A1
The present invention relates to compounds of Formula (I) described herein and their pharmaceutically acceptable salts, and their use in medicine, in particular as Trkantagonists.  
WO/2016/005878A1
Compounds of Formula I are disclosed and methods of treating viral infections with compositions comprising such compounds (Formula I)  
WO/2016/002853A1
The purpose of the present invention is to provide a novel compound that is capable of activating glycogen synthase but hardly activates receptor PPAR and shows high safety. Provided is a compound represented by general formula (I) or a ...  
WO/2016/003158A2
The present invention relates to a new compound for inhibiting binding between a DX2 protein and a p14/ARF protein, and a medical use thereof. A review of the in vitro and in vivo anticancer effect of the compound shows that the compound...  
WO/2015/192198A1
A method is described for treating a peroxisome biogenesis disorder by administering to an individual in need thereof an effective amount of an autophagy inhibitor. Uses, compositions, and commercial packages are also described. The pero...  
WO/2015/191752A1
The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein W, B, n, m, A', R1, R2, and R3 are described herein. The compounds are inhibitors to th...  
WO/2015/190489A1
 The purpose of the present invention is to provide a useful prodrug compound of a naphthofuran compound. The present invention pertains to a compound represented by general formula (IA): (the symbols in the formula are as stated in th...  
WO/2015/188073A1
This disclosure is directed to agonists of the apelin receptor (APJ) and uses of such agonists.  
WO/2015/182686A1
The present invention addresses the problem of providing a medicinal composition and, in particular, a compound suitable for treating nocturia. Under the expectation that nocturnal urinary frequency could be reduced via an antidiuretic a...  
WO/2015/181470A1
The invention relates mainly to a method for producing a composition of glycidyl ethers synthesised from furan derivatives (furan glycidyl ethers), partly characterised by azeotropic distillation performed under reduced pressure and with...  
WO/2015/177083A1
The invention belongs to the fields of pharmaceutical industry, and particularly to an improved stereoselective synthesis of intermediate compounds for the preparation of gliflozins, for example canagliflozin or structurally similar glif...  
WO/2015/174695A1
The present invention relates to a novel bicyclic derivative that has an inhibitory activity against sodium-glucose linked transporters (SGLTs) present in the intestines and kidneys, or a pharmaceutically acceptable salt, isomer, hydrate...  
WO/2015/169854A1
The invention provides a method for the preparation of regioisomerically pure intermediates which are useful for the preparation of carboxy-fluorescein-type compounds. Such compounds have broad applications within bio-conjugation and/or ...  
WO/2015/169412A1
The invention relates to carbazole, dibenzofurane, dibenzothiophene and fluorene derivatives which are substituted with electron-deficient heteroaryl groups, in particular for use as triplet matrix materials in organic light emitting dev...  
WO/2015/167199A1
The present invention relates to an electron transport material and an organic electroluminescent device comprising the material in an electron transport layer. Tthe compounds according to the present invention as an organic electron tra...  
WO/2015/160772A1
The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, R4, R5, R6, R7, R8, X, Z1and Z2 are defined in the specification.  
WO/2015/158908A1
The present invention relates to small molecule compounds and their use in the treatment of diseases, in particular viral diseases, in particular hepatitis C virus (HCV).  
WO/2015/158206A1
A C-aryl indican derivative represented by formula (I), and a pharmaceutical composition thereof and a preparation method therefor, as well as uses of the C-aryl indican derivative and a pharmaceutically acceptable salt or pharmaceutical...  
WO/2015/158426A1
The invention relates to aryl substituted heterocyclyl sulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis ...  
WO/2015/156417A1
The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases ...  
WO/2015/144282A1
The invention relates to an inorganic-organic hybrid compound as an ion compound, composed of an inorganic cation and an organic anion active substance and optionally, an organic anion fluorescent dye.  
WO/2015/143185A1
Provided herein is the design and synthesis of novel molecular rotor fluorophores useful for detection of amyloid or amyloid like proteins. The fluorophores are designed to exhibit enhanced fluorescence emission upon associating with amy...  
WO/2015/140717A1
The present invention relates to compound of Formula (I) or pharmaceutically acceptable enantiomers, salts or solvates thereof. The invention further relates to the use of the compounds of Formula I as TDO2 inhibitors. The invention also...  
WO/2015/129782A1
Provided is a selective EP2 agonist exhibiting excellent safety. A compound represented by general formula (I) (all the symbols in general formula (I) are as indicated in the description), a salt thereof, an N-oxide thereof, solvates of ...  
WO/2015/123722A1
This invention relates to compounds of the formula (I):The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the...  
WO/2015/123595A1
Disclosed herein, inter alia, are prodrug compositions and methods of using the same for treatment and detection of disease. Specifically, disclosed herein is a compound of formula (I) having spiro-fused 1,2,4-trioxolane and piperidine r...  
WO/2015/117202A1
The present invention relates broadly to anti-cancer agents. In particular, the present invention relates to selected benzopyran compounds, the preparation thereof, and their use in methods for treating cancer and reducing the incidence ...  
WO/2015/115507A1
Provided is a compound represented by formula (I) [wherein each symbol is as defined in the description] or a pharmaceutically acceptable salt thereof. This compound has an excellent TRPA1 antagonistic activity, which makes it possible t...  
WO/2015/113455A1
The invention provides fluorogenic compounds and probes that can be used as reagents for measuring, detecting and/or screening superoxide. The fluorogenic compounds of the invention can produce fluorescence colors, such as green, yellow,...  
WO/2015/114660A1
The present invention relates to novel compounds of the general formula (I), which are selective and peripherally acting KOR agonist, their tautomeric forms, their enantiomers, their diastereoisomers, their stereoisomers, their pharmaceu...  
WO/2015/115613A1
The present invention provides: a good balanced resist which has high sensitivity without deteriorating basic physical properties of a chemically amplified resist such as resolution and line edge roughness (LER); and a compound for resis...  
WO/2015/112754A1
Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, Z1, Z2, and n are as defined in the specification, are useful in treating conditions or disorders prevented by or...  
WO/2015/112445A1
Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, R3, R4, R5, R6, and X are as defined in the specification, are useful in treating conditions or disorders pre...  
WO/2015/061247A3
The present invention relates to pyridine, pyrimidine, pyrazine, and pyridazine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.  
WO/2015/103756A1
The present invention provides compounds of Formula (I), and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the th...  
WO/2015/104684A1
Disclosed are compounds having the formula (I): wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP...  
WO/2015/104677A1
The present invention provides a compound of formula I, or an isotopic form, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a solvate, a polymorph, a prodrug, N-oxide or S-oxide thereof; and processes for their preparati...  
WO/2015/103509A1
Described are RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions ...  
WO/2015/101916A1
An improved process for the preparation of empagliflozin is disclosed. Novel intermediates of formulas (13) and (14) for the preparation of empagliflozin are also disclosed, wherein R1 and R2 are independently hydrogen or hydroxyl protec...  
WO/2015/100524A1
The present invention relates to a method for producing silymarin. The method comprises: pressing silybum marianum seeds to obtain silymarin powder, and soaking the silymarin powder by using alkaline water; extracting, by using acetone, ...  
WO/2015/069979A3
Sulfated and unsulfated flavonoid oligomers as inhibitors of cancer stem cells (CSCs) are provided. In particular, sulfated flavonoid dimers are shown to selectively inhibit CSCs growth and self-renewal both in vitro and in vivo.  
WO/2015/092610A1
The present invention relates to compounds of Formula (I) described herein and their pharmaceutically acceptable salts, and their use in medicine, in particular as Trk antagonists.  
WO/2015/095767A1
Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a f...  
WO/2015/084021A1
The present invention relates to a novel organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent compound according to the present invention can be used in a light-...  
WO/2015/082642A1
Dental composite comprising (i) a polymerizable composition obtainable by reacting a mixture comprising: (a) x equivalents of one or more compounds of the following formula (I), wherein U is an (l+1)-valent hydrocarbon group which may co...  
WO/2015/084796A1
Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof;. whereinRl,R2,R3,R4, R5, R6, Ql, Q2,yl, and Y2are as defined in the disclosure. Also disclosed are compositions containing the compounds of F...  
WO/2015/074124A1
The present invention relates to anti-tropomyosin compounds, processes for their preparation, and methods for treating or preventing a proliferative disease, preferably cancer, using compounds of the invention.  
WO/2015/074328A1
The present invention belongs to the technical field of organic chemistry, and specifically relates to a method for preparing rosuvastatin sodium. The method provided by the invention comprises: reducing 4-p-fluorophenyl-6-isopropyl-2-(N...  
WO/2015/077193A1
There are disclosed compounds that are inhibitors of EZH2, pharmaceutical compositions containing said compounds and methods of treating hyperproliferative, inflammatory, infectious, and immunoregulatory disorders and diseases, utilizing...  

Matches 401 - 450 out of 7,137